Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Mortality
RCT 3-armed trial	256 people with suspected PCP; 181 people with confirmed diagnoses (only those with confirmed diagnoses were evaluated further)	Mortality 2 months 2/58 (3%) with clindamycin–primaquine 4/64 (6%) with TMP–SMX	RR 0.55 95% CI 0.10 to 2.90 P >0.2 for clindamycin-primaquine v TMP-SMX		Not significant
RCT	116 people with suspected PCP; 87 people with confirmed diagnoses (only those with confirmed diagnoses were evaluated further)	Mortality 35 days 1/45 (2%) with clindamycin–primaquine 2/42 (5%) with TMP–SMX	RR 0.47 95% CI 0.04 to 4.96 P = 0.33		Not significant